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The identification of selective glucocorticoid receptor (GR) modi-
fiers, which separate transactivation and transrepression proper-
ties, represents an important research goal for steroid pharmacol-
ogy. Although the gene-activating properties of GR are mainly
associated with undesirable side effects, its negative interference
with the activity of transcription factors, such as NF-B, greatly
contributes to its antiinflammatory and immune-suppressive ca-
pacities. In the present study, we found that Compound A (CpdA),
a plant-derived phenyl aziridine precursor, although not belonging
to the steroidal class of GR-binding ligands, does mediate gene-
inhibitory effects by activating GR. We demonstrate that CpdA
exerts an antiinflammatory potential by down-modulating TNF-
induced proinflammatory gene expression, such as IL-6 and E-
selectin, but, interestingly, does not at all enhance glucocorticoid
response element-driven genes or induce GR binding to glucocor-
ticoid response element-dependent genes in vivo. We further show
that the specific gene-repressive effect of CpdA depends on the
presence of functional GR, displaying a differential phosphoryla-
tion status with CpdA as compared with dexamethasone treat-
ment. The antiinflammatory mechanism involves both a reduction
of the in vivoDNA-binding activity of p65 as well as an interference
with the transactivation potential of NF-B. Finally, we present
evidence that CpdA is as effective as dexamethasone in counter-
acting acute inflammation in vivo and does not cause a hypergly-
cemic side effect. Taken together, this compound may be a lead
compound of a class of antiinflammatory agents with fully disso-
ciated properties and might thus hold great potential for thera-
peutic use.
cytokine  glucocorticoid receptor  inflammation  NF-B
G lucocorticoids (GC) are steroid hormones involved in theregulation of developmental and metabolic processes and
stress responses. They act via binding to the glucocorticoid receptor
(GR), a transcription factor belonging to the superfamily of thy-
roidsteroid nuclear hormone receptors. Steroidal ligands, such as
the synthetic agonist dexamethasone (DEX), bind to GR and
induce a conformational change in the cytoplasmic receptor, re-
sulting in nuclear translocation of ligand-bound GR. GR can
regulate its target genes in either a positive or negative way. Positive
regulation is mainly mediated by direct binding of ligand-activated
homodimerized GR onto inducible enhancer elements in the gene
promoter, called glucocorticoid response elements (GREs).On the
other hand, GR negatively interferes with the activity of transcrip-
tion factors, such as NF-B, which drive proinflammatory genes. It
is widely accepted that the beneficial, antiinflammatory potential of
the GR primarily resides in its ability to negatively modulate
proinflammatory cytokines, whereas concomitant side effects are
mainly the consequence of its transactivating capacities (1, 2).
NF-B is a ubiquitous heterodimeric transcription factor, usually
composed of a p65 and a p50 subunit, anchored to an inhibitor
molecule I-B. Upon stimulation of cells with TNF, LPS, irradia-
tion, or viral infection, I-B- is degraded, allowing activated
NF-B to regulate its target genes in the nucleus (3). Genes
activated by NF-B are implicated in immune responses and code
for cytokines, such as IL-6 and IL-8, enzymes, such as inducible
nitric-oxide synthase and cyclooxygenase-2, and adhesion mole-
cules, such as E-selectin and intracellular adhesion molecule (4, 5).
At present, GCs still remain the most effective drugs for the
treatment of inflammatory disorders. However, their use is limited
by the constellation of adverse effects associated with chronic
steroid use. Side effects include osteoporosis, muscle wasting,
hypertension, behavioral alterations, and disorders of glucose and
lipid metabolism (6). Current research has focused on the identi-
fication of so-called dissociated GCs, which still elicit the antiin-
flammatory effects of GCs but exhibit reduced side effects (7, 8).
Compound A (CpdA), or 2-(4-acetoxyphenyl)-2-chloro-N-
methyl-ethylammonium chloride, is a stable analogue of the hy-
droxy phenyl aziridine precursor found in the Namibian shrub
Salsola tuberculatiformis Botschantzev (9, 10) (Fig. 1A).
Our results demonstrate that CpdA, although lacking a ste-
roidal structure, is capable of efficiently down-modulating NF-
B-driven genes via GR but, most interestingly, does not at all
stimulate GRE-driven genes, suggesting that it is a completely
dissociated agent. Both CpdA and DEX induce nuclear trans-
location of GR, a prerequisite for its functionality. Finally, we
show that CpdA not only interferes with the DNA-binding
capacity of NF-B, but also directly inhibits the transactivation
capacity of the NF-B p65 subunit via activated GR. Most
interestingly, apart from being an equally effective antiinflam-
matory agent as DEX in a mouse in vivo model, CpdA also
displays a better side effect profile in vivo, because it does not
stimulate hyperglycemia. Taken together, these results lead to
the classification of this plant-derived compound as a nonste-
roidal, NF-B-inhibiting antiinflammatory agent and can thus be
categorized as a so-called SGRM (selective GR modulator) (6).
Materials and Methods
Cytokines and Reagents.Recombinant murine TNF was produced
in our laboratory (11). Dexamethasone was purchased from
Sigma. CpdA was synthesized according to Louw and coworkers
(9). A stock solution was prepared in ethanol, aliquoted, and
stored at 70°C.
Anti-GR (H-300) and anti-p65 Abs were purchased from
Santa Cruz Biotechnology and Biomol, respectively. Anti-GR
phospho-Ser-211 and control anti-GR Abs were generous gifts
fromM. Garabedian (New York University School of Medicine,
New York). Luciferase (luc) reagent was prepared as described
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in ref. 11. Human recombinant GR was purchased from Panvera
(Madison, WI).
Plasmids. IL-6, IL-8, and E-selectin reporter gene plasmids are
described in refs. 12 and 13. pSVhGR and pMMTV-Luc were a
generous gift fromW. Rombauts (Katholieke Universiteit Leuven,
Leuven, Belgium). Plasmids containing GR deletion variants were
kind gifts fromR.M. Evans (HowardHughesMedical Institute, La
Jolla, CA). pLT10hGR cloning strategy can be obtained upon
request. p(GRE)250hu.IL6P-luc was cloned by replacing the B
motifs in p(IL6B)350hu.IL6P-lucwith two consensusGRE sites.
pGal4, pGal4-p65, and pGal4-VP16 plasmids were generously
provided byM. L. Schmitz (University of Bern, Bern, Switzerland).
p(Gal)2-50hu.IL6P-luc is described in ref. 11.
Cell Culture.Used cell lines were cultured in DMEM supplemented
with 5% newborn calf serum and 5% FCS, 100 unitsml penicillin,
and 0.1 mgml streptomycin.
Transfection Procedure. L929sA mouse fibroblast cells, HEK 293T
human embryonic kidney cells or A549 and TC10 cells were either
stably or transiently transfected with various reporter gene con-
structs (see figure legends) by the calcium phosphate precipitation
procedure or by using Lipofectamine (Life Technologies), as de-
scribed in refs. 11 and 14. Induction experiments were performed
at least in triplicate in two independent experiments. Inductions
with DEX or CpdA at the indicated concentration were performed
at 2 h for a total of 8 h, and TNF (2,000 unitsml) was added at
time point zero and left on the cells for 6 h.
After inductions, cells were lysed with lysis buffer (Tropix,
Bedford, MA), and samples were assayed for their reporter gene
activity according to the manufacturer’s instructions (Promega).
RT-PCR.RNAwas isolated fromA549 cells by using TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions. The
reverse transcriptase reaction was done by using MLV enzyme
(Promega) followed by a PCR reaction with Taq polymerase
(Promega) on the obtained cDNA. Primer sets for placental
alkaline phosphatase (hPAP) and GAPDH multiplex PCR are
available upon request.
ELISA.Amurine IL-6 ELISA was performed, using a kit, according
to the manufacturer’s instructions (R & D Systems).
EMSA. NF-B EMSA was performed as described in ref. 11.
Whole-Cell Binding Assays. Competitive whole-cell binding assays
were performed as described by Bamberger et al. (15). Binding data
were analyzed by using PRISM software (GraphPad), using nonlin-
ear regression and assuming competitive binding to one class of
binding sites, to obtain IC50 values  SEM.
Partial Protease Digestion Assay. The protease digestion was per-
formed as described by Miner and coworkers (16).
Immunofluorescence Analysis. The immunostaining technique was
performed essentially as described in ref. 17 by using a 1:200
dilution of the anti-GR antibody (Santa Cruz Biotechnology).
Nuclei were visualized by using propidium iodide staining in-
cluding RNase. Samples were analyzed by using a Zeiss confocal
LSM410microscope, and assessment of intracellular localization
of protein signal was performed in a double-blind fashion.
Chromatin Immunoprecipitation (ChIP) Assay. ChIP assays against
p65 andGRwere performed according to the ChIP kit instructions
(Upstate Biotechnology, Lake Placid, NY). Cells were starved for
48 h in serum-free medium, then solvent-treated or treated as
described in the figure legends. Quantitative PCR analysis of bound
human GILZ and IL-8 promoter DNA was detected by specific
primers described in refs. 18 and 19.
Zymosan-Induced Inflamed Paw Model. Eight-week-old C57BL6J
mice were purchased from Iffa Credo. The experimental setup
contained four groups with seven animals per group. Group 1
received an injection i.p. of 500 l of low endotoxin PBS, followed
30 min later by a s.c. injection of 20 l of zymosan solution (15
mgml in PBS, sterilized) in the right footpad and 20 l of PBS in
the left footpad.Group 2was treated i.p. with 500l of 20%ethanol
solution (solvent for CpdA and DEX) followed 30 min later by
zymosan–PBS injections. Group 3 received 50 g of DEX i.p. (500
l of 0.1 mgml in 20% EtOH) 30 min before zymosan–PBS
treatment, and group 4 was treated with 250 g of CpdA (500 l
Fig. 1. Binding studies of DEX and CpdA to GR. (A) Chemical structures of
CpdA and of DEX. (B) L929sA cells were incubated with 20 nM [3H]DEX in the
absence or presence of varying concentrations of DEX (squares) or CpdA
(circles). The results shown are typical of two independent experiments, where
each condition was performed in triplicate (SEM). (C) In vitro-translated
35S-radiolabeled WT hGR was proteolysed with, respectively, 0, 2, 5, 10, and
25gml trypsin in the presence of the solvent vehicle ethanol, CpdA (10M),
or DEX (10 nM). Protein fragments were separated by SDSPAGE and detected
by PhosphorImager technology. Protected bands, indicated by closed arrows
and showing a doublet (d), correspond to segments of GR that are more
resistant to increasing amounts of trypsin in the presence of ligand as opposed
to the solvent signal [open arrow, single band (s)].
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of 0.5 mgml in 20% EtOH) followed 30 min later by a zymosan–
PBS treatment.
Twenty-four, 48, and 72 h after the zymosan–PBS treatment, the
thickness of both footpads was measured by using a caliper, and the
difference between zymosan- and PBS-injected footpads was com-
pared for all four experimental groups. The study was performed
in a double-blind fashion.
Blood Glucose Determination. Food was removed overnight, and
blood samples were taken by sinus retroorbital punction under
isoflurane anesthesia from C57Bl6 mice after a 16-h fasting period
that was followed by treatment with solvent control PBS, CpdA
(12.5mgkg), orDEX(2.5mgkg) i.p. injected (sixmice per group).
Blood glucose levels were determined according to the instructions
of the Glucotrend 2 kit (Roche Diagnostic).
Results
CpdA Interacts with GR. To investigate whether CpdA directly binds
toGR, two independent competitive whole-cell binding assays were
performed in L929sA cells (Fig. 1B). Both DEX and CpdA were
able to compete with [3H]DEX for binding to the endogenous GR,
with a percentage of displacement up to 81%. Homologous
heterologous curves were analyzed, and similar ratios of EC50
values between DEX and CpdA were obtained for both experi-
ments. In the presented experiment, IC50 values of 25.9 nM (95%
confidence levels are 7.9–84 nM) for DEX and 6.4 nM (95%
confidence levels are 1.9–20.5 nM) for CpdAwere obtained. CpdA
thus displays a slightly higher binding affinity, with an IC504-fold
lower than that of DEX.
To additionally detect whether this interaction leads to a change
in receptor conformation, we performed a trypsin protease diges-
tion experiment (Fig. 1C). The solvent control displays little (one
single band at low trypsin) or no specific band fragmentation after
longer proteolysis. In contrast, both CpdA- and DEX-treated GR
not only resisted longer to high trypsin concentration but was also
cleaved in a different pattern (doublets), as compared with solvent.
These results suggest that, in amanner similar to the positive control
DEX, CpdA does interact with GR.
CpdA Induces Nuclear Translocation of GR but Exhibits No Transacti-
vation Potential on GRE-Driven Gene Expression.Because our data in
Fig. 1B andC suggest thatCpdA can interact withGR (9), we asked
whether this interaction would result in nuclear translocation of
GR. By indirect immunofluorescence analysis, we demonstrated
that incubation with DEX or CpdA leads to a clear shift of
endogenous GR from a predominant cytoplasmic phenotype to a
predominant nuclear phenotype in A549 cells (Fig. 2A; and see
Figs. 7 and 8, which are published as supporting information on the
PNAS web site). Moreover, it was tempting to investigate whether
CpdA could also stimulate GRE-driven gene expression.
Fig. 2B shows that CpdA lacks activity at either concentration on
a p(GRE)2-50-luc construct or a pMMTV-Luc construct (data
not shown), stably integrated in L929sA cells. In contrast and as
expected, DEX, a synthetic steroid ligand forGR, is able to strongly
transactivate this construct. However, when added before DEX,
CpdA is able to functionally compete for GR, leading to lower
transactivation levels of the former (last lane of Fig. 2B). When
looking at the expression of the endogenous GC-inducible enzyme
human placental alkaline phosphatase (hPAP) in A549 cells (Fig.
2C) or the gluconeogenic enzyme glucose-6-phosphatase in
BWTG3 liver cells (data not shown) by RT-PCR analysis, we only
found stimulation by DEX. Finally, we performed a ChIP assay
using a specific primer set for the GILZ promoter, recently de-
scribed to contain two functional GRE elements (18). We did not
detect anyGRoccupancy in CpdA-stimulated cells, whereas we did
see a significant GR occupancy of DEX-treated cells (Fig. 2D).
CpdA Inhibits TNF-Induced IL-6 Protein Production and Transrepresses
TNF-Induced Cytokine Promoter Activities by Means of Negative
Interference with NF-B. The activated GR exerts its antiinflamma-
tory actions by inhibiting the production of proinflammatory
cytokines. Because CpdA induces nuclear translocation of GR, we
tested whether this effect could result in repression of proinflam-
matory gene expression.
Fig. 3A shows that CpdA is able to efficiently lower the basal IL-6
production as well as the TNF-induced IL-6 protein levels in TC10
cells. To determine whether the inhibitory effect of CpdA is
directed at the transcriptional level of NF-B-driven genes, we
additionally tested the NF-B-dependent physiological promoter
construct, pE-selectin-Luc, stably integrated into L929sA cells, and
observed CpdA-mediated inhibition of TNF-induced gene expres-
sion in a dose-responsive manner (Fig. 3B). The same results were
obtained for a human IL-6 promoter construct (p1168hu.IL6P-
luc), as well as a for human IL-8 promoter construct (p1481.IL8P-
luc), stably integrated in L929sA cells (data not shown). Previous
studies in our group have designated NF-B as the most important
transcription factor involved in TNF-mediated IL-6 gene induction
(13). Accordingly, we found that CpdA efficiently inhibits the
TNF-activated recombinant reporter gene construct
p(IL6B)350hu.IL6Pluc in a dose-dependent manner (Fig. 3C).
CpdA Repression of NF-B-Driven Genes Depends on the Presence of
GR. Regardless of the translocation experiment, the fact that CpdA
does not stimulateGRE-dependent gene expression and selectively
Fig. 2. Effect of DEX and of CpdA on GRE-dependent gene expression and
translocation of GR. (A) A549 cells were serum-starved in phenol red-free
medium for 8 h before induction with solvent control (NI), 1M DEX, or 10M
CpdA for 45 min. After fixation, cells were subjected to immunostaining with
anti-GR, followed by anti-rabbit-Alexa 488 as a secondary Ab (GR). Propidium
iodide staining (PI) was used to visualize nuclei. (B) L929sA cells with stably
integrated p(GRE)2-50-lucwere solvent-treated or induced with DEX (1M),
CpdA (1 or 10 M), or various combinations thereof for a total period of 8 h.
Cell lysates were assayed for luciferase activities and normalized for protein
content. Promoter activities are expressed as relative induction factor, i.e., the
ratio of expression levels recorded either at induced and noninduced condi-
tions, with the latter taken to be 1. Assays were performed in triplicate, and
results are representative of at least two independent induction experiments.
(C) A549 cells were solvent-treated or induced with DEX (1 M) or CpdA (1 or
10M) for a total period of 8 h. RNA was isolated and reverse transcribed. The
resulting cDNA was subjected to PCR analysis with primers to detect the
household gene GAPDH (loading control) or the gene coding for human
placental alkaline phosphatase in the same sample. (D) ChIP on the GILZ
promoter was performed with the GR Ab on A549 cells treated for 2 h with
either solvent, DEX (1 M) or CpdA (1 and 10 M). GR enrichment on the GRE
was determined by correcting the SYBR green quantitative PCR signal for the
bound fraction to that of the input fraction. The reaction was performed in
triplicate. ctrl, IgG Ab control.








represses NF-B-driven genes made us wonder whether this mech-
anism could occur independently of GR.
HEK 293T cells have negligible amounts of endogenous GR
(data not shown). Therefore, we used these cells to test whether the
transrepressive effect of CpdA on NF-B requires the presence of
functional GR. We looked at the effect of DEX and CpdA on
NF-B-driven gene expression with or without introduction of GR
into these cells. Fig. 4 A and B demonstrates that TNF-activated
p(IL6-B)350hu.IL6P-luc expression can be repressed by either
DEX or CpdA but that in both cases the presence of GR is an
absolute prerequisite. Fig. 4 C–E demonstrates that, although the
N-terminal part of GR appears to be dispensable, both the intact
DNA- and ligand-binding domains are important both for CpdA
and DEX to mediate their transrepressive effects.
CpdA Does Not Phosphorylate Ser-211 of GR in Contrast to DEX. The
group of Garabedian (20) recently showed that the transcriptional
activity of GR upon agonist stimulation is correlated with a 10-fold
increase in the phosphorylation status of the Ser-211 residue in the
N terminus of GR. Because CpdA behaves as a completely disso-
ciated, nontransactivating ligand for GR, we were interested to
know how CpdA could affect phosphorylation of this residue.
Fig. 4F shows that DEX is able to enhance the phosphorylation
status of this specific Ser residue at least 10-fold over background
levels, as expected. Interestingly, inductionwithCpdAdoes not lead
to a similar increase in the phosphorylation of Ser-211, nicely
correlating with the lack of CpdA-induced GR-mediated transcrip-
tional activation. Equal amounts of sample loading were verified by
using a non-phosphorylation-specific Ab, which now also reveals
the positive control of 500 ng of human recombinant GR (Fig. 4F
Lower, last lane).
CpdA Interferes with the DNA-Binding Activity of NF-B in Vitro and
in Vivo and also Inhibits the Transactivation Potential of p65.We first
investigated the effect of CpdAonNF-BDNA-binding activity by
gel-shift analysis. From Fig. 5A it can be seen that CpdA at 10 M
affects NF-BDNA-binding activity (lane 8 vs. lane 5), which is in
contrast toDEX(lane 6 vs. lane 5). Supershifts on theTNF-induced
samples demonstrated that the complexes predominantly consist of
p65 and p50 (data not shown). When performing a ChIP experi-
ment to analyze the endogenous p65 recruitment on the IL-8
promoter in vivo, we observed a similar result, i.e., that CpdA
pretreatment lowers p65 recruitment, as comparedwithTNFalone.
Preincubation with DEX also seems to slightly affect the TNF-
induced p65 recruitment at the NF-B-binding site, although a
substantial amount of p65 still remains attached onto the promoter
(Fig. 5B). The activated GR can mediate transrepression of NF-B
by means of a nuclear interference mechanism (11). To investigate
whether CpdA-activated and nuclear-translocated GR also has a
direct inhibitory effect on the transactivation capacities of p65, we
investigated the activity of a Gal4-p65 chimeric protein, stably
transfected into L929sA cells. Fig. 5C demonstrates that CpdA (10
M) is able to inhibit the activity of Gal4p65 almost to the same
extent as DEX (1 M). Gal4 serves as a negative control, whereas
the specificity ofGal4-p65 repression is demonstrated by usingGal4
fused to the viral activator VP16, which is not subject to regulation
by either DEX or CpdA.
CpdA Displays Antiinflammatory Properties in Vivo Without Inducing
Hyperglycemia. To study the possible antiinflammatory effects of
CpdA in vivo, we opted for the zymosan-induced inflamed paw
Fig. 3. Effect of DEX or CpdA on constitutive and TNF-induced IL-6 protein levels and on activated NF-B-dependent reporter gene expression. (A) A murine
IL-6 ELISA was performed with the supernatant culture medium of subconfluent TC10 endothelial cells. Cells were treated with 1 M DEX or 10 M CpdA in the
absence or presence of 2,000 unitsml TNF. DEX or CpdA was added 2 h before TNF for a total period of 8 h. This figure is representative of two independent
experiments. L929sA cells with the stably integrated reporter gene construct pE-selectin-Luc (B) or p(IL6B)350hu.IL6P-luc (C) were either treated with DEX (1
M) or CpdA (1 or 10 M), as indicated, in the absence or presence of 2,000 unitsml TNF. DEX or CpdA was added 2 h before TNF for a total induction period
of 8 h. Plotting of the results is as in Fig. 2A.
Fig. 4. Assaying GR (domain) requirement for inhibition of NF-B-driven gene expression and effect of DEX or CpdA on the specific phosphorylation of GR.
HEK 293T cells were transiently transfected with 100 ng of p(IL6B)350hu.IL6P-luc, 100 ng of a -galactosidase control plasmid, and 200 ng of Mock DNA (A),
pSVhGR (B), or plasmids harboring deletion variants of GR as indicated on the figure (C–E). After transfection, cells were pretreated for 2 h with 1 M DEX or
10 M CpdA, after which, TNF (2,000 unitsml) was added where indicated. All inductions were allowed to continue for another 6 h. (F) A549 cells were induced
for 2 h with CpdA at 10 M or DEX at 1 M. Western blot analysis on total extracts was performed with an anti-GR phospho-Ser-211 Ab or an anti-GR
nonphosphorylation site-specific Ab.
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model. Mice are injected s.c. with zymosan in the footpad, and
swelling is determined at several time points after the injection.
Pretreatment with CpdA (i.p.) is performed to evaluate antiinflam-
matory effects, and DEX (i.p.) was chosen as positive control. In
Table 1, we show the mean of the differences between zymosan-
and PBS-treated footpad for all four groups (see Materials and
Methods) and also indicate whether there are significant differences
between the individual groups by statistic analysis with the Student
t test.
BothDEXandCpdApretreatment show clear antiinflammatory
activities because the swelling is significantly less as compared with
the PBS and ethanol pretreatment groups. At all time points
measured (measurements also performed at 48 and 72 h; data not
shown), there were no significant differences between PBS and
ethanol treatment and no significant differences betweenDEX and
CpdA pretreatment.
The transactivation-mediated increase in blood glucose concen-
tration byGCs reflects the risk for induction of diabetesmellitus (8).
After i.p. treatment in mice, we found that DEX, as expected,
triggered a significant increase (P  0.025) in blood glucose as
compared with controls (Fig. 6). In contrast, CpdA did not at all
lead to a significant increase in blood glucose level. The ANOVA
is used for all analyses, followed by Scheffe´ post hoc tests for treated
vs. control comparisons. The level of significance for all statistical
analyses was set at P  0.05.
Discussion
Although the structure of CpdA is totally different from a normal
steroidal ligand (Fig. 1A), it has been suggested that the biological
effects of CpdA are most likely mediated by GR (9, 10, 21). Our
binding results indicate that CpdA is indeed able to compete with
the specific binding of [3H]DEX to GR for up to 81% (Fig. 1B).
Protease digestions combined with transfection data also suggest
that CpdA interacts with GR, and more specifically, with the
ligand-binding domain of GR (Figs. 1C and 4 C–E). CpdA may,
however, induce a subtly different conformational change of GR.
This hypothesis would also fit with the fact that we found a
differential phosphorylation status of GR (Fig. 4F), which may
correspond to a different allosteric conformation, similarly as has
been described for ER- phosphorylation by the Rsk2 kinase (22).
Fig. 5. Effect of DEX or CpdA on NF-BDNA binding and NF-B transcriptional
activity. (A) L929sA cells were either left untreated or treated with DEX (1M) or
CpdA (1 or 10 M), alone or together with TNF (2,000 unitsml). DEX and CpdA
were added 2 h before TNF, for a total period of 4 h. The total protein extract was
incubated with a 32P-labeled IL-6 NF-B response element, and proteinDNA
complexes were analyzed in an EMSA. Arrowheads indicate the activated B
complex and the constitutively expressed recombination binding protein (RBP)-
J. Lane 9 is a control without protein extract. (B) ChIP was performed with
anti-p65 on A549 cells pretreated for 1 h with DEX (1M) or CpdA (10M) alone,
or together with TNF for another 1 h (lanes 3, 6, and 9) or 2 h (lanes 2, 5, and 8).
The inputs (In) show that the starting chromatin extracts had equal amounts of
the probed regions; the bounds (p65) show enrichment of the IL-8 regions that
contain NF-B response elements. (B Right) ChIP with the IgG negative control
and the corresponding input lane. (C) L929sA cell lines with various stably trans-
fected Gal4 constructs, as indicated in the graph, were transiently transfected
with the p(Gal4)2-50hu.IL6P-luc reporter gene and the -galactosidase-
expressing control plasmid. After transfection, cells were either left untreated or
treated with DEX (1 M) or with CpdA (1 or 10 M) for 8 h.










P value DEX compared
with CpdA group
1 PBS 2.02  0.30 0.381 (NS)
2 Ethanol 1.89  0.23 0.381 (NS)
3 DEX 1.20  0.39 0.0009 (***) 0.0017 (**)
4 CpdA 1.07  0.42 0.0004 (***) 0.0007 (***) 0.5596 (NS)
Mice were injected s.c. with zymosan in the footpad, and swelling was determined at 24 h after the injection.
Pretreatment with CpdA, DEX, or solvent was for 30 min. Means  SD were compared with a Student t test. **
and ***, 0.001  P  0.01 and P  0.001, respectively. NS, not significant.
Fig. 6. Effect of DEX or CpdA on blood glucose levels. Mice were treated for
up to 10 days with either solvent, 2.5 mgkgday DEX or 12.5 mgkgday
CpdA. The blood glucose concentration was determined 3 days before the first
treatment, as well at 8 and 10 days after treatment (mice were fasted 16 h
before the blood samples were taken).








Because the affinity for GR is slightly higher with CpdA than with
DEX, it seems rather unexpected that the effective concentration
needed tomediatemaximal physiological effects is higher for CpdA
than forDEX.However, other examples of ligands exist that display
a difference between receptor affinity and efficacy. For instance,
the phytoestrogen genistein has a higher affinity for ER than for
ER, but its efficacy turns out to be greater with ER than with
ER (23). Even though CpdA can bind to GR and drive it into the
nucleus (Fig. 2A), we found that CpdA does not stimulate endog-
enous GRE-dependent genes or different GRE-driven reporter
genes (Figs. 2 B and C), nor does it induce GR occupancy on an
endogenous GRE-dependent promoter in vivo. CpdA could par-
tially repress DEX-mediated promoter activity on a GRE-driven
reporter gene, when added beforehand, which implies some degree
of competition for GR molecules in the cell. Why the order of
additionmay be important is not easily explained and needs further
studying of binding parameters, such as association and dissociation
kinetics, andor even crystallographic studies. We rejected the
hypothesis that CpdAwould display a general irreversible reactivity
(e.g., alkylation) towardGR andmaking the receptor dysfunctional
by performing ‘‘wash-out’’ experiments (Fig. 8 A and B). Both GR
translocation capability and functionality in reporter gene assays
could be restored after washing out CpdA and replacing it with
DEX.
Most interestingly, we discovered that CpdA was able to effi-
ciently down-regulate the transcription of various TNF-induced and
NF-B-dependent proinflammatory genes, such as IL-6, E-selectin,
intracellular adhesion molecule, and IL-8, as well as IL-6 protein
production (Fig. 3 and data not shown), and thus displays a clear
antiinflammatory action. As for the CpdA-mediated repression
mechanism, we unambiguously established that the presence of
functional GR, and more specifically its second zinc finger and its
intact ligand-binding domain, are needed for this effect (Fig. 4
A–E), whereas the N-terminal part of the GR appears to be
dispensable. The same domains have been reported to be necessary
for GC-mediated repression (24). With regard to specificity, we
further verified that none of the other nuclear receptors from class
II (like PR, AR, MR, and ER) were translocated by CpdA or led
to CpdA-mediated transrepression (see Fig. 9 A and B, which is
published as supporting information on the PNAS web site).
Furthermore, CpdA substantially affects the in vivo NF-B
DNA-binding activity on the IL-8 promoter in A549 cells (Fig. 5B),
confirming the in vitro bandshift assay results of an IL-6 NF-B
probe, using L929sA cell extracts (Fig. 5A). DEX treatment slightly
lowered the in vivoNF-B-binding activity, which seems in contrast
to earlier results by Nissen and Yamamoto (19). This differential
effect may be due to the fact that we have pretreated the cells with
DEX before adding TNF. Just as with GCs, we found that CpdA
interferes with the transactivation potential of a nuclear Gal4-p65
fusion protein (Fig. 5C) and believe that this activity is the more
important mechanism of CpdA-mediated transrepression.
Wang and coworkers (20) identified phosphorylation of Ser-211
in GR as a biomarker for agonist-activated GR, found predomi-
nantly in the nucleus. Our results now suggest that the phosphor-
ylation of Ser-211 is not a prerequisite for nuclear transport of GR,
because CpdA does not phosphorylate this residue to the same
extent as DEX, whereas GR accumulated in the nucleus with both
ligands. The lack of phosphorylation, however, nicely correlates
with the lack of transactivation by CpdA on GRE-driven promot-
ers. Thus, a difference in the phosphorylation status of Ser-211may
reflect differences in transrepression vs. transactivation potential of
GR and consequently may be a valid test system to screen for
dissociated compounds with a more beneficial action profile. Dis-
sociating ligands for GR, with separate transactivation and tran-
srepression capabilities, merit a lot of interest because of their
improved pharmaceutical profiles (25). Some steroidal compounds
with such properties have already been described and characterized
in detail (26, 27). However, not all of these steroids have proven to
be equally successful in vivo as in vitro, with regard to the side effect
profile (28). Hence, the search continues for compounds that elicit
marked antiinflammatory effects but have a minor impact on
unwanted endocrine responses. The recently developed AL-438
(modified progestin scaffold) and ZK 216348 compounds demon-
strate that the principle of an improved therapeutic index, i.e., by
separation of therapeutic effect (transrepression) and side effects
(transactivation) by GR, is possible (7, 8). Such compounds are
called SGRMs (selective GRmodulators) (6). In the present study,
we demonstrate that CpdA clearly displays antiinflammatory char-
acteristics not only in vitro but also in vivo, i.e., in an acute
inflammatory mouse model (Table 1). Moreover, not only did we
find a clear lack of stimulation of endogenous glucocorticoid-
inducible genes by CpdA (Fig. 2C), we also confirmed that a truly
improved side effect profile exists in vivo with regard to the risk of
diabetes induction, by demonstrating a clear lack of hyperglycemia
with CpdA as compared with DEX.
An extensive comparative study of CpdAwith DEX on the other
levels of GR-mediated side effects in vivo may offer insights or
realistic possibilities to ascertain whether CpdA or other analogues
can really contribute to human well-being as effective fully disso-
ciated antiinflammatory drugs.
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